London, 4 July 2018, Consilium Strategic Communications, a global leader in strategic healthcare communications, is proud to have supported the Dementia Discovery Fund (DDF) with its $350 million raise from an influential group of strategic investors committed to developing new medicines for dementia. With this fundraising, DDF has become the largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.
Consilium has worked with the DDF through its launch in October 2015 including 16 investments and several notable fundraises. The fund is managed by SV Health Investors and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), the UK Department of Health and Social Care and the charity Alzheimer’s Research UK (ARUK).
The DDF has a broad and influential investor base which includes the above seven leading pharmaceutical companies, AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, Woodford Investment Management via Woodford Patient Capital Trust (WPCT), the UK’s Department of Health and Social Care and charity Alzheimer’s Research UK.
“With substantial interest in the growing global threat of dementia, Consilium, a healthcare specialist, is delighted to have supported the DDF since its launch. The international reach of the fund, and the stellar team from SV Health Investors make this a uniquely exciting venture to work with.”
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications
To view the DDF’s announcement and latest video please visit https://theddfund.com.
